Fighting against Drug‐Resistant Tumors using a Dual‐Responsive Pt(IV)/Ru(II) Bimetallic Polymer
Open Access
- 22 September 2020
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 32 (43) , e2004766
Abstract
Drug resistance is a major problem in cancer treatment. Herein, the design of a dual‐responsive Pt(IV)/Ru(II) bimetallic polymer (PolyPt/Ru) to treat cisplatin‐resistant tumors in a patient‐derived xenograft (PDX) model is reported. PolyPt/Ru is an amphiphilic ABA‐type triblock copolymer. The hydrophilic A blocks consist of biocompatible poly(ethylene glycol) (PEG). The hydrophobic B block contains reduction‐responsive Pt(IV) and red‐light‐responsive Ru(II) moieties. PolyPt/Ru self‐assembles into nanoparticles that are efficiently taken up by cisplatin‐resistant cancer cells. Irradiation of cancer cells containing PolyPt/Ru nanoparticles with red light generates 1O2, induces polymer degradation, and triggers the release of the Ru(II) anticancer agent. Meanwhile, the anticancer drug, cisplatin, is released in the intracellular environment via reduction of the Pt(IV) moieties. The released Ru(II) anticancer agent, cisplatin, and the generated 1O2 have different anticancer mechanisms; their synergistic effects inhibit the growth of drug‐resistant cancer cells. Furthermore, PolyPt/Ru nanoparticles inhibit tumor growth in a PDX mouse model because they circulate in the bloodstream, accumulate at tumor sites, exhibit good biocompatibility, and do not cause side effects. The results demonstrate that the development of stimuli‐responsive multi‐metallic polymers provides a new strategy to overcome drug resistance.Keywords
Funding Information
- Recruitment Program of Global Experts
- Deutsche Forschungsgemeinschaft (WU 787/8‐1)
- Natural Science Foundation of Anhui Province (1908085MB38)
- National Natural Science Foundation of China (31630027)
- Deutsche Forschungsgemeinschaft (31761133013)
- Chinese Academy of Sciences (E0632911ZX)
- National Basic Research Program of China (2018YFE0117800)
This publication has 40 references indexed in Scilit:
- Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivoBiomaterials, 2017
- A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceAngewandte Chemie International Edition, 2016
- Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolutionProceedings of the National Academy of Sciences, 2016
- Co-Delivery of Cisplatin Prodrug and Chlorin e6 by Mesoporous Silica Nanoparticles for Chemo-Photodynamic Combination Therapy to Combat Drug ResistanceACS Applied Materials & Interfaces, 2016
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsChemical Reviews, 2016
- Cisplatin binding to human serum albumin: a structural studyChemical Communications, 2015
- Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery SystemAngewandte Chemie, 2012
- Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosisProceedings of the National Academy of Sciences, 2010
- The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based ChemotherapyAnnual Review of Pharmacology and Toxicology, 2008
- Rational Design of Platinum(IV) Compounds to Overcome Glutathione-S-Transferase Mediated Drug ResistanceJournal of the American Chemical Society, 2005